What is HC Wainwright’s Estimate for ABEO Q1 Earnings?

Abeona Therapeutics Inc (NASDAQ:ABEO) – Analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Abeona Therapeutics in a research report issued on Monday, March 24th. HC Wainwright analyst R. Selvaraju forecasts that the biopharmaceutical company will earn ($0.10) per share for the quarter. HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.05 EPS and FY2026 earnings at ($0.12) EPS.

Other analysts also recently issued reports about the company. StockNews.com upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Monday. Oppenheimer started coverage on Abeona Therapeutics in a research report on Wednesday, March 5th. They set an “outperform” rating and a $16.00 price target for the company. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Abeona Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $17.50.

Abeona Therapeutics Stock Performance

Shares of ABEO stock opened at $4.99 on Tuesday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. The firm has a market capitalization of $216.92 million, a price-to-earnings ratio of -1.86 and a beta of 1.79. Abeona Therapeutics has a one year low of $3.05 and a one year high of $8.45. The company has a 50 day moving average price of $5.43 and a 200 day moving average price of $5.82.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.19.

Hedge Funds Weigh In On Abeona Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Twinbeech Capital LP acquired a new stake in Abeona Therapeutics in the 4th quarter valued at $58,000. Squarepoint Ops LLC purchased a new stake in shares of Abeona Therapeutics in the fourth quarter worth about $67,000. Jane Street Group LLC purchased a new stake in shares of Abeona Therapeutics in the third quarter worth about $84,000. Oxford Asset Management LLP acquired a new stake in shares of Abeona Therapeutics in the fourth quarter valued at about $118,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in shares of Abeona Therapeutics during the 3rd quarter valued at about $151,000. Hedge funds and other institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.